Loading...
Loading...
Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc.. Spoken Alpha tracks ESLAW's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks ESLAW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.12 | $1.57 | +35.3% | -0.3% | +1.3% |
| Q4 FY2026 | $2.02 | $1.56 | +29.5% | -1.7% | -0.5% |
| Q3 FY2026 | $2.33 | $1.82 | +27.9% | -4.8% | -6.8% |
| Q2 FY2026 | $2.27 | $1.64 | +38.3% | +6.4% | +5.3% |
| Q1 FY2025 | $2.20 | $1.60 | +37.8% | +1.0% | +2.4% |
| Q4 FY2025 | $2.46 | $1.85 | +32.9% | +3.0% | +4.6% |
| Q3 FY2025 | $2.29 | $1.72 | +33.0% | -2.2% | -1.5% |
| Q2 FY2025 | $2.69 | $1.91 | +41.0% | -0.1% | +0.5% |
| Q1 FY2024 | $2.29 | $1.67 | +37.0% | +4.9% | +3.4% |
| Q4 FY2024 | $2.42 | $1.76 | +37.7% | +2.8% | +4.8% |
Spoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
CFO since 2023 • 10/12 beats (83%) • last guidance cut Q1 FY2026
CEO since 2023 • 4/12 beats (33%) • guidance suspended Q1 FY2026
CEO since 2022 • 6/16 beats (38%) • last call held guidance Q1 FY2026
CEO since 2021 • 15/20 beats (75%) • last guidance raise Q1 FY2026
CFO since 2021 • 10/20 beats (50%) • guidance suspended Q3 FY2026
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ESLAW.
curl https://api.spokenalpha.com/v1/companies/ESLAW